KIR3DL1 and neoplasm: Notably, KIR3DL1+ NK cells exhibited rapid recovery (17.1% median at days 28-56, increasing to 41.7-86.0% by days 28-41), suggesting that KIR3DL1-HLA-B interactions may modulate anti-tumor immunity.